ABVC BioPharma (NASDAQ:ABVC) Trading Up 1.5% – Still a Buy?

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s share price rose 1.5% on Thursday . The company traded as high as $2.11 and last traded at $2.08. Approximately 50,801 shares traded hands during mid-day trading, an increase of 1% from the average daily volume of 50,541 shares. The stock had previously closed at $2.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ABVC BioPharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

ABVC BioPharma Stock Performance

The stock has a market cap of $50.54 million, a P/E ratio of -10.40 and a beta of 0.21. The company’s 50 day moving average price is $2.33 and its 200-day moving average price is $2.79.

ABVC BioPharma (NASDAQ:ABVC) last posted its quarterly earnings data on Friday, October 31st. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.80 million during the quarter.

Institutional Investors Weigh In On ABVC BioPharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after buying an additional 6,017 shares during the period. Citadel Advisors LLC purchased a new position in ABVC BioPharma during the 3rd quarter valued at about $48,000. Finally, Millennium Management LLC purchased a new stake in shares of ABVC BioPharma in the 3rd quarter worth about $60,000. 11.38% of the stock is currently owned by institutional investors.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.